Seer, Inc. (SEER)
|Net Income (ttm)||n/a|
|Trading Day||January 19|
|Day's Range||79.20 - 86.55|
|52-Week Range||54.01 - 86.55|
Seer Signs Commercial Agreement to Provide Complete End-to-End Solution for Unbiased, Deep, Rapid and Large-Scale Proteomics
Combination of Thermo Fisher's market leading Orbitrap mass spectrometer portfolio with Seer Proteograph™ Product Suite to expand availability of end-to-end proteomics in new markets Combinati...
REDWOOD CITY, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company focused on enabling exceptional scientific outcomes through the power of unbiased, de...
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider b...
Seer Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
REDWOOD CITY, Calif., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Seer, Inc., a life sciences company focused on enabling exceptional scientific outcomes through the power of unbiased, deep, rapid and s...
The first week of the December IPO market saw eight IPOs and ten SPACs raise $3.9 billion, led by Chinese education technology group 17 Education & Technology Group. Two companies, Ondas and A...
The hot category of initial public offerings in the biotechnology sector continues, with two set to trade Friday: Seer and Silverback Therapeutics. Both priced above their estimated range.
REDWOOD CITY, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Seer, Inc., a life sciences company focused on enabling exceptional scientific outcomes through the power of unbiased, deep, rapid and s...
Redwood City, California-based Seer was founded to develop instruments to analyze proteins for basic research and discovery.
Seer, which provides a proteograph product suite for biomedical research, filed on Thursday with the SEC to raise up to $150 million in an initial public offering.
Seer, Inc. has filed to go public with an IPO on the NASDAQ.
Seer, a life sciences company, engages in developing nanoparticle technology solutions for researchers in the areas of proteomics information. The company develops Proteograph, an integrated solution comprising consumables, automation instrumentation, and proprietary software that performs proteomics analysis. It intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The... [Read more...]
|IPO Date |
Dec 4, 2020
|Stock Exchange |
|Ticker Symbol |
According to 4 analysts, the average rating for Seer, Inc stock is "Buy." The 12-month stock price forecast is 69.67, which is a decrease of -16.83% from the latest price.